Fig. 4From: A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patientsKaplan-Meier curves: a progression-free survival (PFS) and b overall survival (OS) of NSCLC patients receiving nivolumab monotherapy stratified by clearance into 4 quartiles of clearance displayed by Kaplan-Meier methodology: Q1 [first quartile (blue); lowest clearance] - Q4 [fourth quartile (red); highest clearance]Back to article page